A small-molecule SERCA activator can increase ER Ca2+ and has shown efficacy in APP/PS1 mice, supporting SERCA activation as a therapeutic strategy for AD (Krajnak and Dahl, 2018). The gene discussed is APP; the disease is Alzheimer disease.